Teveten Hct is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 12, 2014. Details of Teveten Hct's patents and their expiration are given in the table below.
Get the complete list right in your inbox!
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet,
capsules, liquids etc).
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but Teveten Hct is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Teveten Hct's family patents as well as insights into ongoing legal events on those patents.
Teveten Hct's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Generic Launch
Generic Release Date:
Teveten Hct's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 12, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Teveten Hct Generics:
There are no approved generic versions for Teveten Hct as of now.
Alternative Brands for Teveten Hct
Teveten Hct which is used for managing high blood pressure., has several other brand drugs in the same treatment category .
Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Used for managing hypertension and reducing cardiovascular mortality in stable patients with left ventricular failure or dysfunction post-myocardial infarction.
Used for managing congestive heart failure and hypertension to reduce mortality.
About Teveten Hct
Teveten Hct is a drug owned by Abbvie Inc. It is used for managing high blood pressure. Teveten Hct uses Eprosartan Mesylate; Hydrochlorothiazide as an active ingredient. Teveten Hct was launched by Abbvie in 2001.
Approval Date:
Teveten Hct was approved by FDA for market use on 01 November, 2001.
